SCHEMBL4351863

SCHEMBL4351863

CCSc1ncc(C(=O)c2ccc(OC)c(F)c2)c(N)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 9/20 0.46
ALDH1A1 P00352 7/20 0.46
HPGD P15428 2/20 0.46
POLB P06746 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
CYP11B1 P15538 1/20 0.45
CYP11B2 P19099 1/20 0.45
RAB9A P51151 8/20 0.43
MAPT P10636 5/20 0.43
LMNA P02545 4/20 0.43
MAPK1 P28482 1/20 0.43
HTT P42858 1/20 0.43
NPC1 O15118 6/20 0.42
USP2 O75604 1/20 0.42
TSHR P16473 4/20 0.41
NFKB1 P19838 2/20 0.41
NFKB2 Q00653 2/20 0.41
RELA Q04206 2/20 0.41
RECQL P46063 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4346730 0.84 CDK1 (0.52) SMN1; SMN2ALDH1A1HPGDPOLBTDP1
SCHEMBL4352506 0.84 CDK1 (0.51) SMN1; SMN2ALDH1A1HPGDPOLBTDP1
SCHEMBL4352791 0.84 CDK1 (0.49) SMN1; SMN2ALDH1A1HPGDPOLBTDP1
SCHEMBL4361299 0.83 CDK1 (0.45) SMN1; SMN2ALDH1A1HPGDPOLBTDP1
SCHEMBL4349032 0.82 SMN1; SMN2 (0.45) SMN1; SMN2ALDH1A1HPGDPOLBTDP1
SCHEMBL4356372 0.82 MAPT (0.48) SMN1; SMN2ALDH1A1HPGDPOLBTDP1
SCHEMBL4353088 0.82 MAPT (0.47) SMN1; SMN2ALDH1A1HPGDRAB9AMAPT
SCHEMBL13621473 0.82 CDK1 (0.51) SMN1; SMN2ALDH1A1HPGDPOLBTDP1
SCHEMBL4356448 0.81 SMN1; SMN2 (0.51) SMN1; SMN2ALDH1A1HPGDPOLBTDP1
SCHEMBL4348389 0.81 SMN1; SMN2 (0.44) SMN1; SMN2ALDH1A1HPGDPOLBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 US claimed
US-20060229330-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID J 2006-10-12 US claimed
US-20040162303-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID JOSEPH (US) 2004-08-19 US claimed
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 US disclosed
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 US disclosed
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 US disclosed
US-7157455-B2 4-Aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2007-01-02 US disclosed
US-20060229330-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID J 2006-10-12 US disclosed
EP-1628619-A2 4-AMINOPYRIMIDINE-5-ONE F.HOFFMANN-LA ROCHE AG (CH) 2006-03-01 EP disclosed
US-20040162303-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID JOSEPH (US) 2004-08-19 US disclosed
WO-2004069139-A2 4-AMINOPYRIMIDIN-5-YL-METHANONE DERIVATIVES FOR INHIBITION OF CDK4 ACTIVITY F.HOFFMANN-LA ROCHE AG (CH) 2004-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162303-A1 4-aminopyrimidine-5-one derivatives CDK4, CDKL4, CDK6 SMN1; SMN2 2994/4885ALDH1A1 915/4885HPGD 909/4885
US-20060229330-A1 4-aminopyrimidine-5-one derivatives CDK4, CDKL4, CDK2 SMN1; SMN2 2768/4885ALDH1A1 1191/4885HPGD 1163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.